Dana-Farber Cancer Institute | Strategic Alliance Partners

Paolo Tarantino, MD, PhD, discusses the efficacy and safety of adjuvant THP in patients with stage II to IIIA HER2-positive breast cancer.

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Jacob Sands, MD, discusses ways to manage the toxicities associated with the DLL3 inhibitor tarlatamab in the treatment of patients with SCLC.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Dr Wen discussed the significance of the FDA approval of dordaviprone for patients at least 1 year of age with H3K27M-mutated diffuse midline glioma.

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

Findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine if weight loss following breast cancer treatment can reduce the risk of cancer recurrence and extend survival.

Alice T. Shaw, MD, PhD, has been named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

Dana-Farber Cancer Institute researchers have developed a blood test that could help transform the diagnosis and monitoring of multiple myeloma.

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss ongoing research to watch in ovarian cancer.

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for neoadjuvant IMNN-001 plus chemotherapy in advanced epithelial ovarian cancer.

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for radical up-front surgery in advanced ovarian cancer from the TRUST trial.

A study led by Dana-Farber Cancer Institute researchers found that chemoimmunotherapy before surgery for stage III NSCLC can help make surgery possible. 

Drs Morgans and Shore discuss the significance of the FDA approval of darolutamide plus ADT for metastatic castration-sensitive prostate cancer.

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for dostarlimab plus niraparib in advanced ovarian cancer.

Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.

Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyper‐CVAD in adult and AYA patients with ALL.